The findings of more recent studies on patients with predominately stage IV NSCLC also indicated an association between higher CRP levels and shorter survival time in patients with distant metastases treated with chemotherapy, immunotherapy or both42–47. The gene discussed is CRP; the disease is non-small cell lung carcinoma.